DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sepsis

Intervention: Meropenem (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
AstraZeneca CRR Central and Eastern Europe, Hungary Medical Director, MD, Study Director, Affiliation: AstraZeneca

Summary

This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.

Clinical Details

Official title: Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of days from randomization to recovery from sepsis among those patients who survived the trial period

Endpoint considered in conjunction with observed mortality rates to determine whether any reduction in time to recovery from sepsis

Secondary outcome:

Number of days from randomization to ready to discharge from the ICU

Number of days from randomization until patient is discharged from the ICU

Number of days on first line antibiotic therapy

Number of days from randomization until patient is discharged from hospital

Proportion of patients who achieve clinical cure from sepsis following first line antibiotic therapy

Proportion of all patients who are ready to discharge from the ICU following antibiotic therapy

Mortality rate due to "all causes" in the meropenem group and the standard antibiotic therapy group

Mortality rate due to infection in the meropenem group and the standard antibiotic therapy group

Health Economics-Resource utilization for main treatment and diagnostic procedures, tools and materials

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male and female subjects aged ≥ 18, requiring intensive care treatment related to

secondary nosocomial sepsis, who require potent broad spectrum intravenous antibiotic therapy. Exclusion Criteria:

-

Locations and Contacts

Research Site, Baja, Hungary

Research Site, Budapest, Hungary

Research Site, Eger, Hungary

Research Site, Kecskemet, Hungary

Research Site, Kistarcsa, Hungary

Research Site, Miskolc, Hungary

Research Site, Pecs, Hungary

Research Site, Siofok, Hungary

Research Site, Szekesfehervar, Hungary

Research Site, Szolnok, Hungary

Research Site, Szombathely, Hungary

Research Site, Veszprem, Hungary

Additional Information

Starting date: January 2002
Last updated: January 25, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017